Tekla Capital Management’s Ovid Therapeutics OVID Stock Holding History

Tekla Capital Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-372,733	Closed	-$1.46M	–	189
2021 Q2	$1.46M	Hold	372,733	–	–	0.05%	165
2021 Q1	$1.5M	Hold	372,733	–	–	0.05%	171
2020 Q4	$861K	Hold	372,733	–	–	0.03%	184
2020 Q3	$2.14M	Hold	372,733	–	–	0.08%	153
2020 Q2	$2.75M	Hold	372,733	–	–	0.1%	145
2020 Q1	$1.11M	Hold	372,733	–	–	0.05%	172
2019 Q4	$1.55M	Hold	372,733	–	–	0.06%	163
2019 Q3	$1.21M	Hold	372,733	–	–	0.05%	153
2019 Q2	$690K	Sell	372,733 -124,244	-25%	-$222K	0.03%	175
2019 Q1	$880K	Hold	496,977	–	–	0.04%	165
2018 Q4	$1.2M	Sell	496,977 -38,847	-7%	-$177K	0.05%	154
2018 Q3	$3.04M	Hold	535,824	–	–	0.11%	123
2018 Q2	$4.18M	Hold	535,824	–	–	0.16%	103
2018 Q1	$3.79M	Hold	535,824	–	–	0.15%	104
2017 Q4	$5.29M	Buy	535,824 +373,287	+230%	+$3.43M	0.2%	87
2017 Q3	$1.39M	Sell	162,537 -373,287	-70%	-$3.11M	0.05%	131
2017 Q2	$5.23M	Buy	+535,824	New	+$7M	0.19%	88

Other funds holding OVID

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Tekla Capital Management's OVID Position: Q3 2021 in Review

Tekla Capital Management sold out of Ovid Therapeutics (OVID) in Q3 2021, closing a stake of 372,733 shares — an estimated $1.46M sold.

Tekla Capital Management first reported a position in OVID in Q2 2017 and held it in 17 quarters. The position peaked at $5.29M in Q4 2017. 72 funds tracked by Wall St. Rank hold OVID as of Q3 2021.

Tekla Capital Management reported no remaining Ovid Therapeutics position as of Q3 2021 after selling out during the quarter.
Tekla Capital Management sold 372,733 Ovid Therapeutics shares in Q3 2021, an estimated $1.46M.
Tekla Capital Management first reported a position in Ovid Therapeutics in Q2 2017 and held it in 17 quarters.
Tekla Capital Management's Ovid Therapeutics position peaked at $5.29M in Q4 2017.
72 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.